Arizona State Retirement System Makes New $77,000 Investment in Evolus, Inc. (NASDAQ:EOLS)

Arizona State Retirement System acquired a new position in shares of Evolus, Inc. (NASDAQ:EOLS – Get Rating) in the 4th quarter, according to its most recent filing with the SEC. The fund acquired 10,288 shares of the company’s stock, valued at approximately $77,000.

Other large investors also recently bought and sold shares of the company. Metropolitan Life Insurance Co NY acquired a new position in shares of Evolus during the 1st quarter worth approximately $26,000. Point72 Hong Kong Ltd boosted its holdings in shares of Evolus by 979.7% during the 1st quarter. Point72 Hong Kong Ltd now owns 2,343 shares of the company’s stock worth $26,000 after purchasing an additional 2,126 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Evolus by 453.6% during the 3rd quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company’s stock worth $51,000 after purchasing an additional 5,221 shares during the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of Evolus during the 3rd quarter worth approximately $54,000. Finally, BNP Paribas Arbitrage SA boosted its holdings in shares of Evolus by 164.4% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,753 shares of the company’s stock worth $90,000 after purchasing an additional 4,821 shares during the last quarter. 45.41% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EOLS has been the topic of several recent research reports. HC Wainwright boosted their target price on Evolus from $15.00 to $16.00 in a report on Wednesday, May 10th. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Evolus in a report on Thursday, March 9th.

Evolus Trading Down 3.4 %

EOLS opened at $8.98 on Friday. Evolus, Inc. has a one year low of $6.51 and a one year high of $14.30. The stock has a market capitalization of $511.14 million, a PE ratio of -7.07 and a beta of 1.84. The business’s 50 day moving average price is $8.79 and its 200 day moving average price is $8.51. The company has a debt-to-equity ratio of 10.37, a quick ratio of 1.49 and a current ratio of 2.07.

Evolus (NASDAQ:EOLS – Get Rating) last released its quarterly earnings data on Wednesday, March 8th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). Evolus had a negative net margin of 45.84% and a negative return on equity of 268.53%. The business had revenue of $43.65 million during the quarter, compared to analyst estimates of $43.48 million. As a group, equities research analysts expect that Evolus, Inc. will post -0.55 EPS for the current year.

Insider Activity at Evolus

In other Evolus news, insider David Moatazedi sold 6,110 shares of the business’s stock in a transaction that occurred on Monday, March 27th. The stock was sold at an average price of $8.47, for a total value of $51,751.70. Following the sale, the insider now owns 609,567 shares of the company’s stock, valued at $5,163,032.49. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 5.40% of the stock is currently owned by insiders.

About Evolus

(Get Rating)

Evolus, Inc is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.